# A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct07172802/  
OnCo record `nct07172802` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GI-108 in non-small-cell lung cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and renal cell carcinoma, run by GI Innovation, Inc., now recruiting.

## Summary

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07172802 by GI Innovation, Inc., with 76 participants planned, started 2025-04-22 and due to reach its primary completion in 2027-02. Interventions recorded: GI-108.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07172802
- Phase: 1/2
- Setting: An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as a Single Agent in Patients With Advanced or Metastatic Solid Tumors
- Sponsor: GI Innovation, Inc.
- Enrolled: 76

## Sources

- ClinicalTrials.gov NCT07172802: https://clinicaltrials.gov/study/NCT07172802

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)

---
JSON: https://onco.cc/api/v1/entities/nct07172802.json